两度延期后易明医药控制权变更尘埃落定：姚劲波6.62亿入主，股票今日复牌

Core Viewpoint - The control of Xizang Yiming Xiya Pharmaceutical Technology Co., Ltd. is set to change as the controlling shareholder Gao Fan signs a share transfer agreement with Beijing Fuhai, transferring 43,855,883 shares, representing 23% of the company's total shares, at a price of 15.10 yuan per share, totaling 662.22 million yuan [1][2]. Share Transfer Details - The share transfer involves Gao Fan transferring 43,855,883 circulating shares, which constitutes 23% of the total shares of the company (190,677,750 shares) to Beijing Fuhai at a price of 15.10 yuan per share, amounting to a total of 662,223,833 yuan [2]. - The share transfer price is based on the company's financial statements as of April 30, 2025, and considers the company's industry performance and future development prospects [2]. Rights and Obligations Post-Transfer - Upon completion of the transfer, the acquirer will enjoy the rights and obligations of a shareholder as stipulated by Chinese laws and the company's articles of association [3]. - The company reported a cumulative undistributed profit of 355,542,076.29 yuan as of the end of the first quarter of 2025, which will be shared among all shareholders according to their shareholding ratio [3]. Stock Resumption - The company's stock (trading name: Yiming Pharmaceutical, stock code: 002826) will resume trading on June 4, 2025 [4]. Company Performance Overview - Yiming Pharmaceutical has experienced significant fluctuations in net profit, with a decline of over 60% in 2023, followed by a recovery in 2024, and a further decrease in the first quarter of 2025 [5]. - The company's net profits from 2022 to 2024 were recorded at 44 million yuan, 15 million yuan, and 46 million yuan respectively [5]. - In the first quarter of 2025, the company reported operating revenue of 149 million yuan, a year-on-year decrease of 7.41%, and a net profit attributable to the parent company of 18.79 million yuan, down 32.64% year-on-year [5].